Acute myeloid leukemia (AML) is a heterogeneous clonal stem cell malignancy in which immature hematopoietic cells proliferate and accumulate in bone marrow, peripheral blood, and other tissues. This results in inhibition of normal hematopoiesis, characterized by neutropenia, anemia, thrombocytopenia, and the clinical features of bone marrow failure. AML comprises 90% of all acute leukemias in adults, with approximately 13,000 new cases and 9000 deaths in the United States in 2009. The annual incidence is approximately 3.5 per 100,000 and increases with age, with approximately a 10-fold increased risk between ages 30 (1 case per 100,000) and 65 years (1 case . . . [Full Text of this Article]